Unnecessary Antibiotic Use and Patient Safety

The role of antibiotic stewardship

Unnecessary Antibiotic Use and Patient Safety

Like any medication, antibiotics carry certain risks. While critical for treating a wide range of infections, these drugs also increase a patient’s risk of developing Clostridium difficile infections or experiencing an adverse drug event, such as an allergic reaction. Because of these risks, it is important to use antibiotics only when medically necessary. However, many antibiotics prescribed in the United States are unnecessary or inappropriate.1 Improved antibiotic stewardship is needed, not only to curb the threat of antibiotic resistance but also to avoid exposing patients to unnecessary risks. 

Risk of C. difficile 

The use of antibiotics can put patients at an increased risk for developing C. difficile infections, which can sometimes result in life-threatening diarrhea. One hospital-based study found that use of a broad-spectrum antibiotic (a drug that acts against a wide range of bacteria) nearly tripled a patient’s risk of C. difficile infection.2 An analysis of multiple studies found that patients who received antibiotics were seven times more likely to contract a community-associated C. difficile infection compared with patients who had not received antibiotics.3 Community-associated infections occur in patients with no recent health care exposure.4 

The Centers for Disease Control and Prevention considers C. difficile an “urgent threat” to the nation’s public health system.5 A recent study estimated that there were nearly 500,000 C. difficile infections in the United States in 2011, resulting in 15,000 deaths.6 C. difficile infections can occur at any age but are most frequent in people 65 and older.7 The death rate associated with these infections is also significantly higher among older patients, particularly for C. difficile infections associated with health care settings.8 Recurrent C. difficile infections are a particular concern, because repeated infections create ongoing sources for transmission of the bacteria.9 

Occurrence of adverse drug events 

Antibiotic use is also associated with a number of other adverse drug events, which are estimated to cause more than 140,000 emergency room visits a year.10 The majority of these visits are due to allergic reactions, which can range from minor rashes to life-threatening responses. Antimicrobials are the most common cause of adverse drug events in children, accounting for nearly 30 percent of ER visits (mostly due to penicillins and cephalosporins).11

The role of antibiotic stewardship in improving patient safety 

Antibiotic stewardship programs are essential for minimizing the inappropriate use of antibiotics across health care settings. These programs aim to ensure that antibiotics are used only when indicated—that is, to treat bacterial infections—and at the right dose and duration of therapy. The potential impact these programs can have on patient safety is clear.12 One study estimated that a 30 percent reduction in broad-spectrum antibiotic use in hospitals could result in a 26 percent reduction in hospital-associated C. difficile infection.13 

The CDC has published core elements of stewardship programs to guide hospitals in the development and implementation of these programs.14 Beyond hospitals, long-term care facilities and outpatient offices can also implement interventions tailored to their needs and resources. 

The use of antibiotics will always carry a risk, both to public health and individual patients. However, increased stewardship efforts can help minimize the risk by ensuring that antibiotics are used responsibly.

Endnotes

  1. U.S. Centers for Disease Control and Prevention, Antibiotic Resistance Threats in the United States, 2013 (2013), http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.
  2. Scott Fridkin et al., “Vital Signs: Improving Antibiotic Use Among Hospitalized Patients,” Morbidity and Mortality Weekly Report 63, no. 9 (2014): 194–200, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6309a4.htm?scid=mm6309a4_w.
  3. Abhishek Deshpande et al., “Community-Associated Clostridium difficile Infection and Antibiotics: A Meta-Analysis,” Journal of Antimicrobial Chemotherapy 68 (2013): 1951–1961, http://dx.doi.org/10.1093/jac/dkt129.
  4. U.S. Centers for Disease Control and Prevention, “Technical Information – Clostridium difficile Tracking,” last updated December 14, 2015, http://www.cdc.gov/hai/eip/cdiff_techinfo.html.
  5. U.S. Centers for Disease Control and Prevention, Antibiotic Resistance Threats.
  6. Fernanda C. Lessa et al., “Burden of Clostridium difficile Infection in the United States,” New England Journal of Medicine 372 (2015): 825–834, http://dx.doi.org/10.1056/NEJMoa1408913.
  7. Ibid.
  8. Ibid.
  9. Ibid.
  10. Nadine Shehab et al., “Emergency Department Visits for Antibiotic-Associated Adverse Events,” Clinical Infectious Diseases 47 (2008): 735–743, http://dx.doi.org/10.1086/591126.
  11. Florence T. Bourgeois et al., “Pediatric Adverse Drug Events in the Outpatient Setting: An 11-Year National Analysis,” Pediatrics 124, no. 4 (2009): e744–e750, http://dx.doi.org/10.1542/peds.2008-3505.
  12. Pranita D. Tamma, Alison Holmes, and Elizabeth Dodds Ashley, “Antimicrobial Stewardship: Another Focus for Patient Safety?” Current Opinion in Infectious Diseases 27, no. 4 (2014): 348–355, http://dx.doi.org/10.1097/QCO.0000000000000077.
  13. Fridkin et al., “Vital Signs,” 194–200.
  14. U.S. Centers for Disease Control and Prevention, Core Elements of Hospital Antibiotic Stewardship Programs, last updated May 7, 2015, http://www.cdc.gov/getsmart/healthcare/implementation/core-elements.html.

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.